December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Edgewise Therapeutics, Inc. - Common Stock (NQ:EWTX)

23.57 +0.25 (+1.07%)
Streaming Delayed Price Updated: 2:08 PM EST, Dec 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Edgewise Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Why Comera Life Sciences Shares Jumped 101%; Here Are 74 Biggest Movers From Yesterday ↗
Gainers Akero Therapeutics, Inc. (NASDAQ: AKRO) shares jumped 136.8% to settle at $29.05 on Tuesday after the company's Phase 2b HARMONY study met its primary endpoint for both the 50mg and 28mg EFX... 
Via Benzinga
News headline image
Edgewise Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
From Edgewise Therapeutics
Via Business Wire
News headline image
Recap: Edgewise Therapeutics Q2 Earnings ↗
  Edgewise Therapeutics (NASDAQ:EWTX) reported its Q2 earnings results on Thursday, August 4, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Edgewise Therapeutics Announces Proposed Offering of Common Stock
From Edgewise Therapeutics
Via Business Wire
News headline image
Edgewise Therapeutics Announces Positive 4-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)
From Edgewise Therapeutics
Via Business Wire
News headline image
Edgewise Therapeutics Announces FDA Authorization for Phase 2 Clinical Trial of EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (DMD)
From Edgewise Therapeutics
Via Business Wire
News headline image
RBC Capital Says This Dystrophy Stock 'Is Worth A Look' ↗
 
Via Benzinga
News headline image
Edgewise's Dystrophy Candidate Lowers Muscle Damage Biomarkers ↗
 
Via Benzinga
News headline image
Recap: Edgewise Therapeutics Q1 Earnings ↗
Edgewise Therapeutics (NASDAQ:EWTX) reported its Q1 earnings results on Wednesday, May 11, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For August 25, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Edgewise Therapeutics Reports Second Quarter 2022 Financial Results
From Edgewise Therapeutics, Inc.
Via Business Wire
News headline image
Stocks That Hit 52-Week Lows On Friday ↗
On Friday, 166 companies set new 52-week lows. Points of Interest From Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was... 
Via Benzinga
News headline image
Edgewise Therapeutics to Present at the Wedbush PacGrow Healthcare Conference on August 9
From Edgewise Therapeutics
Via Business Wire
News headline image
6 Blue-Chip Stocks to Sell Now ↗
This article is about 6 blue-chip stocks to sell now. They are severely overvalued or are likely to move down soon with a recession. 
Via InvestorPlace
News headline image
Edgewise Therapeutics Initiates Mid-Stage Muscular Dystrophies Study ↗
Edgewise Therapeutics (NASDAQ: EWTX) announced the initiation of the CANYON Phase 2 clinical trial evaluating EDG-5506 in individuals with Becker Muscular Dystrophy (BMD). 
Via Benzinga
News headline image
Edgewise Therapeutics Now Enrolling CANYON Phase 2 Clinical Trial of EDG-5506 in Individuals with Becker Muscular Dystrophy (BMD)
From Edgewise Therapeutics
Via Business Wire
News headline image
The Daily Biotech Pulse: Thumbs Down For Acadia's Pimavanserin, Pfizer Buys Stake In Valneva, AstraZeneca - Ionis Eplontersen Aces Rare Disease Trial ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Edgewise Therapeutics Announces Positive 2-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)
From Edgewise Therapeutics
Via Business Wire
News headline image
New 2-Month Interim Data from the ARCH Open Label Study of EDG-5506 in Individuals with Becker Muscular Dystrophy (BMD) to be Presented at the Upcoming New Directions in Biology and Disease of Skeletal Muscle Conference
From Edgewise Therapeutics
Via Business Wire
News headline image
Edgewise Therapeutics to Present at Upcoming Investor Conferences
From Edgewise Therapeutics
Via Business Wire
News headline image
Analyst Ratings for Edgewise Therapeutics ↗
Over the past 3 months, 4 analysts have published their opinion on Edgewise Therapeutics (NASDAQ:EWTX) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
News headline image
Edgewise Therapeutics Reports First Quarter 2022 Financial Results
From Edgewise Therapeutics
Via Business Wire
News headline image
Edgewise Therapeutics to Present at Upcoming Investor Conferences
From Edgewise Therapeutics
Via Business Wire
News headline image
Edgewise-Funded Natural History Trial of Becker Muscular Dystrophy (BMD) Now Enrolling
From Edgewise Therapeutics
Via Business Wire
News headline image
Stocks That Hit 52-Week Lows On Wednesday ↗
On Wednesday, 63 companies set new 52-week lows. Noteworthy Mentions In Today's 52-Week Lows: The largest company by market cap to hit a new 52-week low was... 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Thursday ↗
On Thursday, 112 stocks made new 52-week lows. Noteworthy Highlights From Today's 52-Week Lows: Stanley Black & Decker (NYSE:SWK) was the largest firm by market... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Pfizer-BioNTech Apply For Authorization Of 3rd Booster Shot, Sanofi-Seagen Strike Cancer Therapy Pact, Iovance Gets Nod For Cancer Study ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
News headline image
The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings ↗
Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments... 
Via Benzinga
News headline image
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
From Edgewise Therapeutics
Via Business Wire
News headline image
Edgewise Therapeutics to Participate at SVB Leerink 11th Annual Global Healthcare Conference on February 16
From Edgewise Therapeutics
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.